Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

The Bristol Myers Squibb subsidiary RayzeBio has opened a new 77,000-square-foot facility in Indianapolis, Indiana.

Bristol Myers Squibb is preparing to ship a new and possibly life-changing cancer treatment to patients across the world. The ...

Bristol Myers Squibb has opened a $160M radiopharma facility in Indianapolis, scaling up production since acquiring RayzeBio ...

Buy: Novo Nordisk. The global pharmaceutical company operates through two business segments: diabetes and obesity ca ...

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

RLT_Angels Photo RLT Angels Association Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb company ...

RayzeBio, Inc., a wholly-owned subsidiary of Bristol Myers Squibb Company, is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted ...

Nuclidium has raised 79 million Swiss francs ($99 million) as the Swiss and German biotech looks to continue the clinical ...

RLT_Angels Photo RLT Angels Association Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb company.

6 月 2 日，百时美施贵宝（BMS）与 BioNTech 共同宣布达成一项全球性合作协议，双方将联合开发及商业化 BioNTech 旗下双特异性抗体候选药物 BNT327（原Biotheus的 PM8002），用于多种实体瘤治疗。根据协议内容，BioNTech 与 BMS 将协同推进这一临床候选药物的开发进程，这一合作动态在生物医药行业引发广泛关注。

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...